Abstract
The study of the efficacy of thrombolytic agents in the treatment of acute stroke derives from the observation that stroke is typically an atherothrombotic or thromboembolic process [1, 6], Careful intraarterial infusion of the thrombolytic agents urokinase (u-PA) and streptokinase may lead to thrombus dissolution and clinical improvement in selected patients presenting with acute thrombotic or thromboembolic stroke [1, 2–4 7], This experience has provided the practical background for the evaluation of the relatively fibrin specific agent recombinant tissue plasminogen activator (rt-PA) delivered by intravenous infusion. A predominantly two-chain rt-PA preparation (duteplase, Burroughs Wellcome, Beckenham, UK) has been employed in a prospective open multicenter dose-rate safety and efficacy study of thrombolysis m acute thrombotic and thromboembolic stroke.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
